Matt Hansen
Spago takes Tumorad-01 study to the next level
Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...
Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago...
Tumor clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical publishes positive preclinical data
Preclinical data with Spago Nanomedical's radionuclide concept Tumorad has...
Spago Nanomedical starts phase IIa study in endometriosis
Lund-based Spago Nanomedical recently announced that the company has received...
Spago Nanomedical about the autumn news flow
During the second quarter, the Lunda company Spago Nanomedical carried out a...
Spago Nanomedical moves towards the clinic with Tumorad
Shortly before the end of the year, Lund-based Spago Nanomedical announced that...
Spago Nanomedical steps up with capital injection
The Lund company Spago Nanomedical raises capital via a...
Spago Nanomedical towards a clinic with a clear plan
First North-listed Spago Nanomedical's CEO Mats Hansen told...
Spago Nanomedical on the potential of the projects
Lund-based Spago Nanomedical recently published the first interim report of the year...
Spago Nanomedical looks ahead
First North-listed Spago Nanomedical has started the year with...
Spago Nanomedical on progress with Tumorad
Lund-based Spago Nanomedical presented positive preclinical results this week...